-+ 0.00%
-+ 0.00%
-+ 0.00%

LANTERN PHARMA SECURES FDA CLEARANCE FOR PLANNED PHASE 1B/2 TRIAL OF LP-184 IN BIOMARKER-DEFINED, TREATMENT-RESISTANT NSCLC PATIENTS WITH HIGH UNMET CLINICAL NEED

Reuters·05/12/2025 13:00:03

Please log in to view news